AQST.US Aquestive Therapeutics Inc

Healthcare Pharmaceuticals USA Stocks
3.91 USD
Close of Nov 13, 2026
2.93 6.74
Market cap
USD 491M
P/E
-
P/B
14.15x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AQST.US undervalued?

Graham number

The Graham number of Aquestive Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aquestive Therapeutics Inc fundamental analysis

No fundamental analysis for Aquestive Therapeutics Inc yet.

Aquestive Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used f…

Full company profile